DOC

_ CURRICULUM VITAE

By Frank Miller,2014-05-19 04:48
8 views 0
_ CURRICULUM VITAE

    CURRICULUM VITAE

    Xiang Liu, MD/PhD

    Research Assistant Professor

University Address

     Department of Microbiology and Immunology

     Basic Science Building

     Medical University of South Carolina

     173 Ashley Avenue

     PO Box 250504

     Charleston, SC, 29403

     Email: liux@musc.edu

     Phone: 843.792.8499

     Fax: 843.792.4882

EDUCATION

     1997 2000 PhD Microbiology and Immunology

     National Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute,

    Medical Center of Fudan University (Formerly Shanghai Medical University), Shanghai,

    China

     1994 1997 MS Biochemistry and Molecular Biology

     Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan,

    Shanxi, China

     1987 1992 MD Medicine

     School of Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, China

     1986 1988 BS (Biochemistry and Chemistry)

     Division of Advanced Biochemistry and Molecular Biology, Dept. of Biology, Shanxi

    University, Taiyuan, Shanxi, China

PROFESSIONAL EXPERIENCE

     2004 present Research Assistant Professor and Research group leader, Dept. of Microbiology and

    Immunology, Medical University of South Carolina, SC, USA

     As a research group leader, my work is focused on optimization gene delivery vectors

    that deliver programmed cell death inducing genes (FasL or Apoptin) to kill cancer

    cells (prostate and head and neck origin). The ultimate goal of my research is to

    develop delivery systems that specifically destroy tumor cells while leaving normal

    cells intact. In addition, I also use combining gene therapy with small molecule-based

    therapeutics, which target to ceramide metabolism pathway, to enhance cytotoxicity

    response or sensitize cells to the current therapies. To date these studies have

    determined novel mechanisms by which prostate cancer cells or head and neck cells

    develop resistant to induction of apoptosis and thus to most current standard

    treatments in clinical medicine. The new compounds develop show promise in

    overcoming this type of resistance and will be tested in the clinic in the future.

     2001 - 2004 Group Leader /HIV Diagnostics, GenPhar, Inc., Mt. Pleasant, SC, USA

     1. I developed a new viral diagnostic method for HIV including a sensitive new

    Phenotypic Assay to support antiviral drug resistance testing. In addition, I developed a

    Quantitative new Assay for measuring neutralizing antibody responses following

    immunization with candidate vaccines, and a new high-throughput screening (HTS) Assay

    for anti-HIV drug discovery. The drug resistance assay represents the latest

    development in phenotypic assay technology. It is capable of directly detecting and

    quantifying anti-HIV drug resistance in patients. Compared to competing technologies,

    this assay is more sensitive, accurate, efficient and applicable to all classes of

    anti-HIV drugs. The drug discovery assay is a highly proficient in vitro drug-screening

    tool, based on the use of our proprietary indicator cell system that will allow us to

    assist other pharmaceutical companies in the efficient identification and validation of

    new antiviral agents against HIV-1.

     2. I also generated a new lymphoid cell-based cell line that supports the replication of

    all HIV strains and a vaccine platform for developing candidate vaccines for HIV,

    Marburg and Ebola.

     2000 2001 Assistant Professor, National Laboratory for Oncogenes and Related Genes, Shanghai

    Cancer Institute, Medical Center of Fudan University (Formerly Shanghai Medical University)

    Shanghai, China.

     My primary responsibilities were to develop an effective gene therapy

    retroviro-vector for treating diseases of the central nervous system and related tissues

    including glioma, a deadly, metastatic, primary brain tumor.

    SELECTED TECHNICAL SKILLS

     Molecular Biology

     DNA Cloning and sub-cloning

     PCR, nest PCR, RT-PCR and Real time-PCR

     Microarray

     DNA and RNA Extraction from tissues or cultured cells

     Southern/dot blot, Northern blot and Western blot analysis

     Cell Biology

     Apoptosis assay (TUNEL, Hoechst staining, DNA ladder)

     Cell cycle analysis

     Flow Cytometric Assay

     SOFT-AGAR assay for colony formation

     Cell proliferation assay

     Virology

     HIV propagation in normal donor PBMC or in immortal cell line

     Anti-HIV drug IC50 (NRTI or NNRTI) assay

     Murine retroviral pseudo-type virus assay

     Anti-HIV neutralization assay

     Biochemistry

     Gel Filtration

     SDS PAGE

     Affinity Chromatography

     Immunology

     ELISA for cytokine detection 51 CTL and NK cells response Cr- release cytotoxicity assay

     Immuno-histochemistry

     Zoology

     Tumor-bearing mice model generation

     Mouse injection

     Animal anatomy

    GRADUATE REASEARCH:

     1997 - 2000 PhD Candidate, National Laboratory for Oncogenes and Related Genes, Shanghai

    Cancer Institute, Medical Center of Fudan University (Formerly Shanghai Medical University)

    Shanghai, China.

     1. The primary goal of my doctoral thesis was to study synergistic anti-tumor

    Effects induced by co-Gene transfer. We developed a series of novel non-viral gene

    delivery systems targeting receptors expression to transfer exogenous gene into cancer

    cells with high efficiency and targeting ability. We employed a new strategy using our

    vector systems, the GE7 system targeting EGF-receptors which are over-expressed in

    many kinds of tumor cells, for tumor-specific gene therapy. The cytokine gene GM-CSF

    and cell cycle regulated gene p21 were transferred simultaneously in vivo and in vitro,

    where we achieved a remarkable anti-tumor effect.

     2. Reconstitution of the human Immune-system in SCID mice: Functional immune

    system in SCID mice was successfully reconstituted with normal human peripheral blood

    mononuclear cells.

    1994 1997 Graduate student, Department of Biochemistry and Molecular Biology, Shanxi Medical

    University, Taiyuan, Shanxi, China

     Construction of hHGF expression system: Successfully designed both a prokaryotic

    and eukaryotic expression system by means of production of HGF.

    PUBLICATIONS

     28. Liu X, Elojeimy SN, Turner LS, Mahdy Ayman EM, Zeidan Y, Bielawska A, Bielawski J, Dong

    J-Y, El-Zawahry AM, Guo G-W, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Tavassoli M,

    Norris JS. Acid ceramidase inhibitors: A novel target for cancer therapy. Frontiers in Bioscience, In

    Press, 2007.

     27. Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, Elojeimy S, Norris JS and Hannun

    YA. Novel Analogs of D-e-MAPP and B1. Part 2. Signature Effects on Bioactive Sphingolipids.

    Bioorganic & Medicinal Chemistry, Pending in Revision, 2007.

     26. Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, Elojeimy S, Norris JS and Hannun

    YA. Novel Analogs of D-e-MAPP and B1. Part 1. Synthesis and Biological Evaluation as Potential

    Anticancer Agents. Bioorganic & Medicinal Chemistry, Pending in Revision, 2007.

    25. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AEM, Turner LS, Cheng J, Bielawska A,

    Bielawski J, Keane TE, Obeid LM, Hannun YA, Norris JS , Liu X. The Functional Effects of Acid

    Ceramidase Over-expression in Prostate Cancer Progression and Resistance to Chemotherapy. Cancer

    Biology and Therapy, 9:1-6, 2007.

    24. Karahatay S, Thomas K, Koybasi S, Senkal CE, ElOjeimy S, Liu X, Bielawski J, Day TA, Gillespie MB,

    Sinha D, Norris JS, Hannun YA, and Ogretmen B. Clinical Relevance of Ceramide Metabolism in the

    Pathogenesis of Human Head and Neck Squamous Cell Carcinoma (HNSCC): Attenuation of

    C18-ceramide in NSCC Tumors Correlates with Lymphovascular Invasion and Nodal Metastasis.

    Cancer Letter, Accepted, 2007.

    23. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, Szulc ZM, Norris K, Zeidan YH,

    Hannun YA, Bielawska A, Norris JS. Lysosomotropic acid ceramidase inhibitor induces apoptosis in

    prostate cancer cells. Can Chemother Pharmacol, In Press, 2007. 1122. Elojeimy S, Liu X., McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, Meacham WD,

    Mahdy A EM, Saad AF, Turner LS, Day TA, Dong JY, Bielawska A, Hannun YA, Norris JS. Role

    for acid ceramidase in resistance to FasL: novel therapeutic approaches based on combination of 1acid ceramidase inhibitors and FasL gene therapy. Molecular Therapy, 15(7):1259-63, 2007. Co-

    First Authors.

    21. Liu X, Zeidan YH, Holman DH, El-Zawahry AM, Elojeimy SN, Guo G, Bielawska A, Bielawski J,

    Rubinchik S, Dong J-Y, Keane TE, Tavassoli M, Hannun YA, Norris JS. Involvement of

    Sphingolipids in Apoptin-induced Cell Killing. Molecular Therapy 11(3):444-451, 2006.

    (Commentary: Chada, S., and Ramesh, R. Apoptin Studies Illuminate Intersection between

    Lipidomics and Tumor Suppressors. Mol Ther 15: 7-9, 2007) 20. Elojeimy SN, Holman DH, Liu X, El-Zawahry AM, Villani M, Cheng JC. Mahdy A, Zeidan Y,

    Bielawska A, Hannun YA, Norris JS. New Insights on the Use of Desipramine as an Inhibitor for

    Acid Ceramidase. FEBS Letters 580:4751-4756, 2006.

    19. Liu X, El-Zawahry AM, Holman DH, Elojeimy SN, Guo G, Bielawska A, Bielawski J, Rubinchik

    S, Dong J-Y, Tavassoli M, Hannun YA, Norris JS. Modulation of Ceramide Metabolism Enhances

    Viral Protein Apoptin’s Cytotoxicity in Prostate Cancer. Molecular Therapy, 14(5):637-646, 2006.

    (Commentary: Chada, S., and Ramesh, R. Apoptin Studies Illuminate Intersection Between

    Lipidomics and Tumor Suppressors. Mol Ther 15: 7-9, 2007) ,18. Norris JS, Bielawska A, Day T, El-Zawahri A, Elojeimy S, Hannun Y Holman D, Hyer M, Landon

    C, Lowe S, Dong JY, McKillop J, Norris K, L. Obeid, Rubinchik S, Tavassoli M, Tomlinson S,

    Voelkel-Johnson C, and Liu X. The Combined Therapeutic Use of AdGFPFasL and Small

    Molecule Inhibitors of Ceramide Metabolism in Prostate and Head and Neck Cancers: A Status

    Report. Cancer Gene Therapy, 13:1045-1051, 2006.

    17. Elojeimy S, McKillop JC, El-Zawahry AM, Holman DH, Liu X, Schwartz D, Day TA, Dong JY,

    Norris JS. FasL Gene Therapy: a new therapeutic modality For Head and Neck Cancer. Cancer

    Gene Therapy, 13:739-745, 2006.

    16. Liu X, Tian PK, Ju DW, Zhang MH, Yao M, Cao XT, Gu JR. Systemic genetic transfer of

    p21WAF-1 and GM-CSF utilization of a novel oligopeptide based EGF receptor targeting polyplex.

    Cancer Gene Therapy 10(7): 529-539, 2003. 15. Liu X, Tian P, Yu Y, Cao X, Yao M, Gu J. Enhanced Anti-tumor Effects of EGF R-targeted p21

    and GM-CSF Gene Transfer on Established Murine Hepatoma by Peritumoral Injection. Cancer

    Gene Therapy 9(1): 100-108, 2002.

    14. Liu Xiang, Tian P, Gu J. Non-viral gene delivery system in gene therapy. Foreign Med. Sci.

    Cancer Section, 28(3): 189-191, 2001.

    13. Han J, Tian P, Liu X, Yao M, Gu J. Inhibition of the growth of human hepatoma cell line both in

    vitro and in vivo by transducing CKI gene p21 with GE7 targeting gene delivery system. Sci China

    (Ser C), 43(6): 523-527, 2000.

    12. Liu X, Han J, Tian P, Gu J. In Vitro Inhibitory Effect on Growth of Human Glioma Cells with p21

    Gene Mediated by A Novel Gene Delivery System. Chin J Cancer Biother, 7(1): 11-14, 2000.

    11. Liu X, Tian P, Gu J. Advances in Combined Gene Therapy on Tumor. Foreign Med. Sci. Cancer

    Section, 27(5): 257-259, 2000.

    10. Gao Y, Liu X, Wang H, Kang Y, Niu B, Cheng N. Expression of Human ?-IFN in NRK Cells. J

    Shanxi Med Univ, 31(1): 14-17, 2000.

    9. Liu X, Tian P, Gu J. Expression of Transthyretin Gene in Yeast Pichiapastoris. Acta

    Bioengineering Sinica, 15(4): 428-433, 1999.

    8. Gao Y, Liu X, Wang H, Kang Y, Niu B, Cheng N. Construction of An Efficient Prokaryotic

    Expression System for Producing ?-IFN Protein. J Shanxi Med Univ, 30(4): 295-298, 1999. 7. Liu X, Gao Y, Wang H, Cheng N, Niu B. Expression of Human HGF in CHO Cells. J Shanxi Med

    Univ, 29(3): 193-196, 1998.

    6. Liu X. Advances in Study of Hepatocyte Growth Factor. J Shanxi Med, 26(2): 177-180, 1997.

    5. Cui X, Gao Y, Wang H, Liu X. Protection Effects of Hippophae Rhamnodes L. Juice with or

    without Supplemented Selenium on Oxidant Damage Induced by Smoking in Rats. Chin J Prev Med,

    30(2): 87, 1996.

    4. Cui X, Gao Y, Wang H, Liu X. Protection Effects of Hippophae rhamnodes L. Juice with

    supplemented slenium on oxidative damage induced by smoking. Chin J Public Health, 15(3): 190,

    1996.

    3. Hu L, Liu J, Li Y, Liu X, Guo G. Clinical Observation of Lipid Peroxide, Superoxide Dismutase

    and Glutathione Peroxidase in the Serum of Graves’ disease Patients. J Shanxi Med, 24:11-12, 1995

    2. Cui X, Gao Y, Wang H, Liu X. Effects of Passive Smoking on Health Status in Rats. Chin J Public

    Health, 13(4): 246-247, 1994.

    1. Cui X, Gao Y, Wang H, Liu X. Effects of Smoking on the Growth, Cellular Immunity and Levels of

    Sialic Acid in Serum of Rats. J Shanxi Med Univ, 25(4): 322-324, 1994.

BOOK CHAPTERS

     Liu X, Elojeimy S, Turner LS, Mahdy AEM, Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry

    AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Tavassoli M, Norris JS. Implementation of stacid ceramidase inhibitors as adjuncts to increase the efficacy of cancer therapy. In: Gene Therapy, 21

    Century’s Center of Excellence Program of Japanese Ministry of Education and Science. Eds: Ochiai T,

    Shimada H, Tagawa M. Medical View, Co., Ltd., Chiba Japan, pps. 58-65, 2007.

INVITED EDITORIALS, REVIEWS, ARTICLES

     Norris JS and Liu X. The Status and Promise of Cancer Gene Therapy. Asia-Pacific Biotech News (APBN)

    9(17), September, 2005.

PHD THESIS

     Synergistic anti-tumor effects of p21 combined with GM-CSF mediated by a non-viral GE7 gene delivery

    system on murine hepatoma.

PRESENTATIONS

    5. The role of Acid Ceramidase in Prostate Cancer Radio-sensitivity. 15th International Conference

    on Gene Therapy of Cancer, Dallas, TX, September 28, 2007.

    4. Acid Ceramidase May Play a Key Role in Resistance to Cancer Gene Therapy. 14th International

    Conference on Gene Therapy of Cancer, Dallas, TX, September 18, 2006.

    3. Inhibition of Acid Ceramidase expression by small interfering RNA sensitizes human prostate

    cancer cells to Apoptin induced cell death. American Society of Gene Therapy Annual Meeting,

    Baltimore MD. May 31-June 4, 2006

    2. Involvement of the acid sphingomyelinase pathway in Apoptin-induced apoptosis. International

    Society for Cell and Gene Therapy of Cancer Annual Meeting, Shenzhen, China. December 9-11,

    2005. th1. Novel non-viral vectors in gene therapy. The 150 Xiangshan Scientific Meeting held in Beijing, a

    national level academic workshop convened regularly in Xiangshan (Fragrance) Hills in Beijing.

    The meeting was attended by 40-odd top-level Chinese experts in the field, Theme for this session

    was “Strategy for Research and Development of Gene Therapy.” Oct. 28 to 30, 2000.

    ABSTRACTS 23. Mahdy AEM, Liu X, Zeidan YH, Cheng J, El-Zawahry A, HannunYA , Bielawski J, Keane TE,

    Tavassoli M, Taha IM, Hammouda MH, Norris JS. Acid Ceramidase Upregulation in Response to

    Prostate Cancer Radiotherapy: a Target for Radio-Sensitization. AUA Meeting, Abstract #: 94749,

    May 2007.

    22. Mahdy AyEM, Liu X, Zeidan YH, Cheng J, El-Zawahry A, Turner LS, Saad A, Elojeimy SN, HannunYA , Bielawski J, Keane TE, Tavassoli M, Taha IM, Hammouda MH, Norris JS.

    Radiation Therapy Upregulates Coxsackie-Adenovirus Receptor in Prostate Cancer Cells and

    Sensitizes Prostate Cancer to Fas Ligand Gene Therapy. AUA Meeting, Abstract #: 94706, May

    2007.

    21. Turner LS, Holman DH, Cheng JY, Cheng JC, El-Zawahry A, Elojeimy S, Liu X. Mahdy Ayman

    EM, Meacham W, Saad AF, Bielawski J, Zdzislaw S, Norris K, Zeidan YH, Hannun YA,

    Bielawska A, Norris JS. Acid ceramidase inhibition as a future treatment option for prostate cancer.

    ASGT 10th Annual Meeting Washington State Convention & Trade Center, Seattle, WA, Abstract

    #591, May 30 - June 3, 2007.

    20. Norris JS, Elojeimy S, Mahdy Ayman EM, Saad A, Turner LS, Meacham W, Bielawska A,

    Bielawski J, Zdzislaw S, Dong, JY, Keane T, Day TA, Hannun YA, Liu X. Targeting acid thceramidase, a new strategy to enhance combination therapy to cancer. BIT’s 5 Anniversary

    Conference & Expo of International Drug Discovery Science and Technology, Shanghai, China,

    May 31- June 5, 2007.

    19. Norris JS, Elojeimy S, Mahdy Ayman EM, Saad A, Turner LS, Meacham W, Bielawska A,

    Bielawski J, Zdzislaw S, Dong, JY, Keane T, Day TA, Hannun YA, Liu X. Targeting acid thceramidase, a new strategy to enhance combination therapy to cancer.4 International Charleston ththCeramide Conference, Pacific Grove, CA, March 7 -11, Abstr. # 92, 2007.

    18. Bai A, Szulc ZM, Bielawski J, Mayroo N, Liu X, Norris JS, Hannun YA, Bielawska A. Signature

    effect of novel analogs of D-e-MAPP and B13 on bioactive sphingolipids in MCF7 carcinoma cells.

    Hollings Cancer Center Cancer Drug Discovery and Development: Bridging Academic and Industry

    Partnerships Spring Symposium, The Sanctuary, Kiawah Island, SC, Poster Presentation #1, March

    23-24, 2007

    17. Mahdy Ayman EM, Liu X, El-Zawahry Ahmed M, Cheng J, Elojeimy S, Turner LS, Saad A.

    Hannun YA, Keane TE, Taha MI, Hammouda HM, Norris JS. The acid ceramidase inhibitor

    LCL385: A promising prostate cancer radio-sensitizer. Hollings Cancer Center Cancer Drug

    Discovery and Development: Bridging Academic and Industry Partnerships Spring Symposium,

    The Sanctuary, Kiawah Island, SC, Poster Presentation #20, March 23-24, 2007.

    16. Norris JS, Elojeimy S, Mahdy Ayman EM, Saad A, Turner LS, Meacham W, Bielawska A,

    Bielawski J, Zdzislaw S, Dong, JY, Keane T, Day TA, Hannun YA, Liu X. Targeting acid

    ceramidase, a new strategy to enhance combination therapy to cancer. Hollings Cancer Center

    Cancer Drug Discovery and Development: Bridging Academic and Industry Partnerships Spring

    Symposium, The Sanctuary, Kiawah Island, SC, Poster Presentation #23, March 23-24, 2007.

    15. Turner LS, Holman DH, Cheng JY, Cheng JC, El-Zawahry A, Elojeimy S, Liu X. Mahdy Ayman

    EM, Meacham W, Saad AF, Bielawski J, Zdzislaw S, Norris K, Zeidan YH, Hannun YA,

    Bielawska A, Norris JS. Acid ceramidase inhibition as a future treatment option for prostate cancer.

    Hollings Cancer Center Cancer Drug Discovery and Development: Bridging Academic and Industry

    Partnerships Spring Symposium, The Sanctuary, Kiawah Island, SC, Poster Presentation #33,

    March 23-24, 2007.

    14. Liu X, Zeidan Y, Elojeimy SN, Holman DH, El-Zawahry AM, Guo G, Bielawska A, Bielawski J,

    Szulc Z, Rubinchik S, Dong J-Y, Keane TE, Tavassoli M, Hannun YA, Norris JS. Implementation

    of Small Molecule Modifiers of Sphingolipid Metabolism as Adjuncts to Increase the Efficacy of

    Gene Therapy. (ISCGT) Annual Meeting, Chiba Japan, October 13, 2006.

    13. Mahdy Ayman EM, Liu Xiang, El-Zawahry AM, Elojeimy SN, Bielawska A, Hannun YA, Keane

    TE, Norris JS. Reversal of PPCL Prostate Cancer Cells Radio-resistance by Degradation of Acid

    Ceramidase Using the Lysosomotropic Drug LCL385. American Society of Gene Therapy Abstract

    #928, Baltimore, MD, May 31 June 4, 2006. 12. El-Zawahry Ahmed M, Liu Xiang, Elojeimy Saeed, Holman David, Mahdy Ayman EM, Bissada

    Nabil K, Rashwan Hashim M, Zdzislaw Szulc, Bielawska Alicja, Bielawski Jacek, Keane Thomas,

    Hannun Yusuf A and Norris James S. Ceramide May Have a Role in Sensitizing ACHN Renal

    Cancer Cells (RCC) to Fas-Induced Apoptosis. American Society of Gene Therapy Abstract #938,

    Baltimore, MD, May 31 June 4, 2006.

    11. Liu Xiang, Elojeimy Saeed, Holman David, Mahdy Ayman EM, Bissada Nabil K, Rashwan

    Hashim M, Zdzislaw Szulc, Bielawska Alicja, Bielawski Jacek, Keane Thomas, Hannun Yusuf A

    and Norris James S. Ceramide analog, LCL-204 Sensitizes DU145 Prostate Cancer Cells (PCa) to

    FasL Gene Therapy through Down-regulation of Survivin. American Society of Gene Therapy

    Abstract #924, Baltimore, MD, May 31 June 4, 2006. 10. Mahdy Ayman EM, Liu Xiang, El-Zawahry Ahmed, Holman David H, Elojeimy Saeed N,

    Bielawska Alicja, Bielawski Jacek, Rubinchik Semyon, Dong Jian-yun , Keane Thomas E,

     Tavassoli Mahvash, HannunYusuf A, Norris James S. Modulation of Ceramide Metabolism

    Enhances Tumor-Selective Viral Protein Apoptin’s Cytotoxicity in Prostate Cancer. American

    Urological Association, Abstract #90805, 2006.

    9. Liu Xiang, Ahmed El-Zawahry, David H. Holman, Saeed Elojeimy, Alicja Bielawska, Jacek

    Bielawska, Mahvash Tavassoli, James S. Norris. The Tumor-Selective Viral Protein Apoptin Is a

    Potential Gene Therapeutic Agent for Prostate Cancer Therapy, #307, American Society of Gene thTherapy, 8 Annual Meeting, St. Louis, MO, June 1-5, 2005.

    8. Elojeimy Saeed N., John C. McKillop, Ahmed M. El-Zawahry, David A. Schwartz, David H.

    Holman, Xiang Liu, Terry Day, Alicja Bielawska, Yusuf A. Hannun, James S. Norris.

    Combination of Fas Gene Therapy and Ceramide Analogues: A Double Edge Sword for the thTreatment of Head and Neck Cancer, #450, American Society of Gene Therapy, 8 Annual

    Meeting, St. Louis, MO, June 1-5, 2005.

    7. El-Zawahry Ahmed, David Holman, Xiang Liu, Saeed Elojeimy, Alicja Bielawska, Jacek Bielawski,

    Zdislaw Szulc, Yusuf Hannun, James S. Norris. A Combination of Ceramide Analogue and FasL

    Gene Therapy Can Be a Potential Novel Therapy for Prostate Cancer, #1011, American Society of thGene Therapy, 8 Annual Meeting, St. Louis, MO, June 1-5, 2005.

    6. El-Zawahry AM, Holman D, Liu Xiang, Bissada N, Rashwan H, Bielawska, Hannun YA, Norris

    JS. Lysosomotropic ceramide LCL-204, acid ceramidase (AC) inhibitor, a potential novel

    chemotherapy for prostate cancer (PCa). American Urological Association, Abstr #6269, May 25,

    2005

    5. Liu Xiang, Holman DH, El-Zawahry AM, Elojeimy S, Bielawska A, Bielawski J, Tavassoli M,

    Norris JS. Involvement of sphingolipids in apoptin-induced cell killing. 3rd International Charleston

    Ceramide Conference. Isle of Palms, SC, Abstr. #078. March 2-6, 2005.

    4. Elojeimy S, Holman DH, El-Zawahry EM, Liu Xiang, Norris JS. Evidence against the use of

    desipramine as a specific inhibitor of acid sphingomyelinase. 3rd International Charleston Ceramide

    Conference. Isle of Palms, SC, Abstr. #056. March 2-6, 2005.

    3. Holman DH, El-Zawahry AM, Liu Xiang, Elojeimy S, Bielawski J, Bielawska A, Szulc Z, Hannun

    Y, Norris JS. Molecular pathway of apoptosis induced by a novel lysomotropic agent/Acid

    Ceramidase inhibitor in the treatment of prostate cancer. 3rd International Charleston Ceramide

    Conference, Abstr. #011. Isle of Palms, SC. March 2-6, 2005.

    2. El-Zawahry AM, Holman DH, Liu Xiang, Elojeimy S, Bielawski J, Bielawska A, Szulc Z, Obeid L,

    Hannun Y, Norris JS. Novel ceramide analogue, acid ceramide LCL-204, augments FasL gene

    therapy in DU145 prostate cancer cells. 3rd International Charleston Ceramide Conference. Isle of

    Palms, SC, Abstr. #055. March 2-6, 2005.

    1. Holman DH, El-Zawahry AM, Liu Xiang, Elojeimy S, Bielawski J, Bielawska A, Szulc Z, Hannun

    Y, Norris JS. Characterization of the apoptosis pathway induced by a novel lysomotropic agent/AC

    inhibitor in the treatment of prostate cancer. Sidney Kimmel Cancer center’s Immune, Vascular and

    Gene Targeting for Cancer Imaging and Therapy, Abstr#029, San Diego, CA. February 28 - March

    2, 2005.

    GRANT AWARDS, PROFESSIONAL SOCIETIES

1994 Series Anti-aging effects induced by Hippophae Rhamnodes L. Juice.

     The project was supported by High Technology Program of Shanxi

     Province, China st 1998 1999 1 Guanghua Award Winner. st 1999 2000 1 Guanghua Award Winner

     2002 present American Society of Gene Therapy

     2002 present American Association of Immunologists

     2002 present American Society for Microbiology

Report this document

For any questions or suggestions please email
cust-service@docsford.com